REPARE THERAPEUTICS INC.
5.10%
2,149,415
1808158
760273102
Jan 12, 2025
Jan 15, 2025, 06:43 PM
Reporting Persons (11)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| ANSBERT GADICKE | Individual | 5.10% | 2,149,415 | 0 | 2,149,415 |
| Todd Foley | Individual | 2.90% | 1,241,564 | 0 | 1,241,564 |
| MPM BioVentures 2014 LLC | Other | 2.90% | 1,241,564 | 0 | 1,241,564 |
| LUKE EVNIN | Individual | 2.90% | 1,241,564 | 0 | 1,241,564 |
| MPM BioVentures 2014 GP LLC | Other | 2.80% | 1,202,755 | 0 | 1,202,755 |
| MPM BioVentures 2014, L.P. | Partnership | 2.70% | 1,127,549 | 1,127,549 | 0 |
| MPM BioImpact LLC | Other | 2.10% | 907,851 | 0 | 907,851 |
| Oncology Impact Fund (Cayman) Management L.P. | Partnership | 2.10% | 907,851 | 0 | 907,851 |
| UBS Oncology Impact Fund L.P. | Partnership | 2.10% | 907,851 | 907,851 | 0 |
| MPM BioVentures 2014 (B), L.P. | Partnership | 0.20% | 75,206 | 75,206 | 0 |
| MPM Asset Management Investors BV2014 LLC | Other | 0.10% | 38,809 | 38,809 | 0 |
Disclosure Items (3)
Common Shares
REPARE THERAPEUTICS INC.
7171 FREDERICK BANTING, SAINT-LAURENT, A8, H4S 1Z9
See rows (11) and (13) of the Filing Persons Owner Profile of this Amendment No. 6 for the aggregate number of Common Shares and percentages of the shares of Common Shares beneficially owned by the Filing Person. The Common Shares are held as follows: * 1,127,549 shares are held directly by BV 2014; * 75,206 shares are held directly by BV 2014(B); * 38,809 shares are held directly by AM BV2014 LLC; and * 907,851 shares are held directly by UBS Oncology. BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2014 and BV 2014(B). BV 2014 LLC is the managing member of AM BV2014 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2014 LLC. BioImpact and Oncology Cayman are the direct and indirect general partners of UBS Oncology and, accordingly, may be deemed to beneficially own the shares held by UBS Oncology. Drs. Gadicke and Evnin and Mr. Foley are the managing directors of BV 2014 LLC and, accordingly, may be deemed to beneficially own the shares held by BV 2014, BV 2014(B) and AM BV2014 LLC. Dr. Gadicke is the managing partner of BioImpact and, accordingly may be deemed to beneficially own the shares held by UBS Oncology. Calculation of the percentage of the shares of Common Shares beneficially owned is based upon 42,510,708 Common Shares outstanding as of November 1, 2024, as reported in the Issuer's Form 10-Q filed with the SEC on November 7, 2024.
See rows (7) through (10) of the Filing Persons Owner Profile of this Amendment No. 6 for the number of shares as to which there is sole power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition.
The Filing Persons sold the following Common Shares in the open market since the date of filing Amendment No. 5: Date of Sale Price Range Ave. Price Sold by Sold by Sold By AM BV Sold by BV 2014 BV 2104(B) 2014 LLC UBS Oncology 1/6/25 $1.3871-$1.48 $1.44 40,293 2,687 1,387 32,442 1/7/25 $1.3396-$1.4799 $1.40 17,004 1,134 585 13,691 1/8/25 $1.255-$1.36 $1.30 30,856 2,058 1,062 24,844 1/10/25 $1.235-$1.405 $1.32 85,612 5,710 2,947 68,931 1/13/25 $1.295-$1.43 $1.37 61,450 4,099 2,114 49,477 1/14/25 $1.265-$1.35 $1.29 17,530 1,169 604 14,114 1/15/25 $1.28-$1.36 $1.31 14,330 956 493 11,538
Inapplicable.
Inapplicable.
Joint Filing Statement